[Status of cholesterol goal attainment for the primary and secondary prevention of atherosclerotic cardiovascular disease in dyslipidemia patients receiving lipid-lowering therapy: DYSIS-China subgroup analysis].

血脂异常 医学 内科学 胆固醇 子群分析 二级预防 疾病 置信区间
作者
Y Li,Shaoping Zhao,P Ye,Xuhe Yan,Yu Mu,Yao Wei,Dekai Hu,DYSIS-China Study Investigators
出处
期刊:PubMed 卷期号:44 (8): 665-70 被引量:6
标识
DOI:10.3760/cma.j.issn.0253-3758.2016.08.006
摘要

To analyze the current status of cholesterol goal attainment for the primary and secondary prevention of cardiovascular disease in dyslipidemia patients using data from the DYSIS-China study.Based on criteria defined in the 2014 China Cholesterol Education Program (CCEP) and the 2007 Chinese guidelines for the prevention and treatment of dyslipidemia in adults, 25 317 dyslipidemia patients enrolled in the DYSIS-China study (from March 2012 to October 2012) were stratified to the atherosclerotic cardiovascular disease(ASCVD) primary prevention and secondary prevention groups. The total cholesterol (TC) target goals were <3.11, 4.14, 5.18, and 6.22 mmol/L, respectively, and the low-density lipoprotein cholesterol (LDL-C) therapeutic goals were less than 1.8, 2.6, 3.4, and 4.1 mmol/L, respectively, for the very high-risk, high-risk, moderate-risk, and low-risk patients in the primary prevention group. The TC targets for the very high-risk and high-risk patients were <3.11 and <4.14 mmol/L, respectively, and the LDL-C targets were <1.8 and <2.6 mmol/L, respectively, in the secondary prevention group. The TC and LDL-C goal attainment rates were calculated for the different risk groups according to the targets values.Totally, 71.09% (n=18 000) of the dyslipidemia patients were grouped into very high and high risk groups, 51.76% (n=13 104) and 48.24% (n=12 213) patients were stratified to primary and secondary prevention of ASCVD. The LDL-C and TC goal attainment rates for the secondary prevention group were 33.09%(4 041 cases) and 21.05% (2 571 cases), respectively. The LDL-C and TC goal attainment rates for the primary prevention group were 52.40% (6 866 cases) and 42.06% (5 511 cases), respectively. Multivariate logistic regression analysis showed that diabetes mellitus(OR=5.75, 4.15, P<0.05), coronary heart disease(OR=5.70, 3.58, P<0.001), and peripheral arterial disease(OR=2.42, 1.49, P<0.05) were risk factors for failure to achieve TC and LDL-C goals, respectively.Despite the widespread application of the 2014 CCEP and 2007 Chinese dyslipidemia guidelines, LDL-C goal attainment among secondary and primary prevention patients remains suboptimal in China. More rigorous guideline adherence is therefore required to increase the LDL-C and TC goal attainment rates and improve the long-term cardiovascular outcomes in Chinese dyslipidemia patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
归宁发布了新的文献求助10
刚刚
称心的水蓉完成签到,获得积分10
1秒前
1秒前
2秒前
王其超发布了新的文献求助10
3秒前
st完成签到,获得积分10
3秒前
研友_VZG7GZ应助老李采纳,获得10
4秒前
科目三应助老李采纳,获得10
4秒前
田様应助慢慢人采纳,获得30
4秒前
乐乐应助老李采纳,获得10
4秒前
天天快乐应助老李采纳,获得10
4秒前
传奇3应助老李采纳,获得10
4秒前
上官若男应助老李采纳,获得10
4秒前
SciGPT应助老李采纳,获得10
5秒前
可爱的函函应助老李采纳,获得10
5秒前
深情安青应助老李采纳,获得10
5秒前
所所应助老李采纳,获得10
5秒前
Lucas应助小伍同学采纳,获得10
5秒前
6秒前
6秒前
GXH应助Barry采纳,获得10
6秒前
FashionBoy应助hysci888采纳,获得10
6秒前
sxb10101给高贵振家的求助进行了留言
6秒前
好运连连发布了新的文献求助10
7秒前
科研通AI6.2应助lie采纳,获得10
8秒前
科研通AI6.1应助潇月采纳,获得10
8秒前
8秒前
10秒前
10秒前
Tammy发布了新的文献求助20
10秒前
落寞易形发布了新的文献求助10
11秒前
11秒前
12秒前
kytkk完成签到,获得积分20
12秒前
13秒前
光亮寄凡发布了新的文献求助30
13秒前
14秒前
传奇3应助听露采纳,获得30
14秒前
慢慢人发布了新的文献求助30
14秒前
小齐天完成签到,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Kinesiophobia : a new view of chronic pain behavior 3000
Les Mantodea de guyane 2500
Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics 2000
Standard: In-Space Storable Fluid Transfer for Prepared Spacecraft (AIAA S-157-2024) 1000
Signals, Systems, and Signal Processing 510
Discrete-Time Signals and Systems 510
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5948926
求助须知:如何正确求助?哪些是违规求助? 7119325
关于积分的说明 15914130
捐赠科研通 5082055
什么是DOI,文献DOI怎么找? 2732308
邀请新用户注册赠送积分活动 1692780
关于科研通互助平台的介绍 1615526